Last reviewed · How we verify
NCT05310539
Early Recovery After "Wedge Resection" Surgery to Remove Lung Mestastasis Secondary to Bone Cancer.
trial testing assessment of the early recovery after wedge resection surgery in Metastasis Lung in 75 participants. Completed in 8 January 2024.
8 January 2024
Quick facts
| Lead sponsor | Istituto Ortopedico Rizzoli |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 8 January 2022 |
| Primary completion | 8 January 2024 |
| Estimated completion | 8 January 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- assessment of the early recovery after wedge resection surgery
Conditions studied
- Metastasis Lung — all drugs for Metastasis Lung →
- Bone Neoplasm — all drugs for Bone Neoplasm →
Sponsor
Istituto Ortopedico Rizzoli — full company profile →
Who can join
12 and older, any sex, with Metastasis Lung or Bone Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After "wedge resection" surgery, the physiotherapy programs proposed in the literature are heterogeneous and there are few data on the outcomes of such treatments in an oncological population for bone cancer. The aim of the study is to describe the early rehabilitation process after wedge resection surgery secondary to bone tumor pulmonary mestasasis, highlightining the possible functional recovery in the short and medium term after surgery and indentifying the possible prognostic factors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05310539
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Istituto Ortopedico Rizzoli trials
Trials by the same sponsor.
- NCT07590882 — Evaluation of Return to Sports Activity After Periacetabular Osteotomy: An Observational Study · enrolling by invitation
- NCT07021222 — Multifactorial Strategies for the Prevention of the Risks of Ulceration in Patients Affected by Diabetic Foot (DARE-DiaF · NA · recruiting
- NCT07360964 — Clear Cell Chondrosarcoma in Italy · NA · active not recruiting
- NCT07140367 — "Transarterial Microembolization (TAME) in Inflammatory Knee Pathology" · recruiting
- NCT07102875 — Ready to Sail 2: A Pilot Study of Sail-Assisted Telerehabilitation in Rare Skeletal Diseases · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05310539 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Ortopedico Rizzoli
- Last refreshed: 18 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05310539.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing